Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

FDA Grants Fast Track Designation to BST02 for Liver Cancer

February 1st 2024

The FDA has granted a fast track designation to the T-cell therapy BST02 for the treatment of patients with all forms of liver cancer.

VDA-1102 Demonstrates Favorable Activity in Mycosis Fungoides

January 29th 2024

VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

January 27th 2024

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

NICE Recommends Talazoparib for Advanced BRCA1/2-Mutant, HER2– Breast Cancer

January 22nd 2024

NICE has recommended talazoparib for the treatment of patients with advanced or metastatic HER2-negative breast cancer with germline BRCA1/2 mutations.

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

January 20th 2024

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

FDA Grants Orphan Drug Designation to PTX-252 for AML

January 19th 2024

The FDA has granted an orphan drug designation to PTX-252 for the treatment of patients with acute myeloid leukemia.

Sequential Treatment With Telomere-Targeted Therapy, Checkpoint Inhibition Produces High DCR in NSCLC

January 18th 2024

Treatment with THIO followed by cemiplimab-rwlc led to a high DCR regardless of dose level in patients with pretreated non–small cell lung cancer.

Ruvidar Demonstrates Potential for Durable Responses in Non–Muscle Invasive Bladder Cancer

January 17th 2024

Treatment with TLD-1433 led to 6-, 12-, and 15-month CR rates of 54%, 38%, and 37%, respectively, in patients with non–muscle invasive bladder cancer.

Frontline Tamibarotene Plus Venetoclax and Azacitidine Induces 100% CR Rate in SELECT-AML-1 Trial

January 16th 2024

Tamibarotene plus venetoclax/azacitidine elicited higher responses rates vs venetoclax/azacitidine in RARA-overexpressed acute myeloid leukemia.

European Commission Approves Subcutaneous Atezolizumab With Enhanze for Several Cancers

January 16th 2024

The European Commission granted marketing authorization for SC atezolizumab co-formulated with Enhanze for all approved indications of IV atezolizumab.

JBI-802 Demonstrates Preliminary Activity in Advanced Solid Tumors

January 15th 2024

Treatment with JBI-802, the first-in-class CoREST inhibitor with dual LSD1 and HDAC6 activity was shown to be safe and active.

FDA Grants Fast Track Designation to RC88 in Platinum-Resistant Recurrent Ovarian Cancer

January 12th 2024

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.

FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs

January 11th 2024

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

FDA Issues CRL to Zolbetuximab for Advanced HER2–, CLDN18.2+ Gastric/GEJ Cancer

January 9th 2024

The FDA has issued a CRL to the zolbetuximab BLA for patients with HER2- gastric or GEJ junction adenocarcinoma whose tumors are Claudin18.2 positive.

Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC

January 5th 2024

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

January 4th 2024

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

Futility Analysis Ends Nivolumab and Relatlimab Evaluation in Pretreated MSS mCRC

January 3rd 2024

The phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer will be discontinued due to futility.

Lung Specialist Finds His “Sweet Spot” at the Intersection of Medicine and Technology

January 1st 2024

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

EV-302 Regimen Bests Chemo in Advanced Urothelial Cancer

December 25th 2023

Findings from the EV-302 trial presented at the 2023 ESMO Congress revealed that the combination of enfortumab vedotin and pembrolizumab may become the preferred frontline standard of care for patients with locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility.

FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL

December 22nd 2023

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.